# MacroGenics, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/MacroGenics, Inc). ## Overview MacroGenics is a U.S. biopharmaceutical company focused on developing antibody-based cancer therapeutics. Its pipeline is built around proprietary platforms such as DART and TRIDENT, and it also earns revenue from collaborations, contract manufacturing, and royalties tied to partnered products. ## Products & services • DART and TRIDENT multispecific antibody platforms • Antibody-drug conjugate (ADC) product candidates • MGD024 bispecific cancer antibody program • Collaborative R&D and licensing agreements • Contract manufacturing of drug substance • Royalty revenue from partnered oncology products - **Proprietary oncology pipeline** (0%) — Internal antibody-based cancer programs, including DART, TRIDENT and ADC candidates. - **Collaborative and other agreements** (58%) — Upfront fees, milestones, research funding and option/license payments from partners. - **Contract manufacturing** (35%) — Drug substance manufacturing and related development services for third parties and partners. - **Royalty revenue** (7%) — Sales-based royalties from partnered products such as ZYNYZ. - DART and TRIDENT multispecific antibody platforms - Antibody-drug conjugate (ADC) product candidates - MGD024 bispecific cancer antibody program - Collaborative R&D and licensing agreements - Contract manufacturing of drug substance - Royalty revenue from partnered oncology products ## Customers MacroGenics sells primarily to biopharma partners rather than end patients, with revenue driven by collaboration agreements, manufacturing services, and royalties. Its commercial counterparties include large pharmaceutical companies such as Gilead, Incyte, TerSera and Sanofi/Provention, while its pipeline is aimed at oncology patients through future partnered or approved products. - **Strategic pharma collaborators** (primary) — Partners such as Gilead and Incyte fund development, exercise options, and share economics on antibody programs. - **Manufacturing services clients** (primary) — Third parties that buy drug substance development and manufacturing capacity for clinical or commercial supply. - **Commercial licensees and royalty payors** (secondary) — Partners that market approved products and remit royalties on sales, such as ZYNYZ-related economics. - **Future oncology patients** (emerging) — Patients with cancer are the ultimate end users of approved product candidates, though MacroGenics usually commercializes through partners. - Large pharma partners funding and advancing oncology programs - Biotech collaborators licensing MacroGenics antibody platforms - Third-party clients buying contract manufacturing services - Commercial partners monetizing approved or out-licensed products - Cancer patients are the end market for future approved therapies ## Geography MacroGenics is headquartered and manufactures in the United States, with key operations centered in Rockville, Maryland. The company also relies on third-party suppliers and contract manufacturers in multiple countries, which creates cross-border sourcing and trade exposure even though the business is primarily U.S.-based. Outside the United States, commercialization is generally expected to occur through third-party partners. - Headquartered in the United States - Manufacturing and commercial site in Rockville, Maryland - Uses third-party suppliers and CMOs in several countries - International commercialization expected through partners - Trade policy and tariff changes can affect supply chain costs ## Strategy MacroGenics is prioritizing advancement of its oncology pipeline while using partnerships to fund development and reduce commercialization burden. It is also expanding contract manufacturing and selective licensing to generate non-dilutive revenue and extend runway into the second half of 2026. - **Advance partnered and internal oncology programs** (medium-term) — Clinical progress is the main driver of future value and partner economics. - **Expand contract manufacturing utilization** (short-term) — Higher production volume can diversify revenue away from milestone timing. - **Preserve liquidity and extend runway** (short-term) — The company remains dependent on external capital and partner payments. - Advance DART, TRIDENT and ADC oncology programs - Use partnerships to fund development and share risk - Grow contract manufacturing revenue from external clients - Monetize approved assets through licensing and royalties - Preserve cash through cost-saving measures and runway management ## Risks MacroGenics faces the classic biotech risk profile: heavy dependence on clinical success, partner execution, and access to capital. Its revenue can swing sharply with milestone timing, while manufacturing and supply-chain complexity add operational and trade-policy exposure. The company also remains vulnerable to competition from better-funded oncology developers and to regulatory or cybersecurity disruptions. - **Financing risk** [high] — The company has ongoing losses and expects to rely on external capital and partner payments. - **Clinical development risk** [high] — Pipeline value depends on successful preclinical and clinical outcomes and regulatory approval. - **Partner concentration and milestone timing** [medium] — A meaningful share of revenue comes from a small number of collaboration agreements. - **Trade and supply-chain disruption** [medium] — The company uses third-party suppliers in several countries and faces tariff/sanction risk. - **Competitive pressure in oncology** [medium] — Large pharma and biotech peers are developing similar antibody and T-cell engager therapies. - Needs substantial additional funding to continue development - Clinical and regulatory failure could halt pipeline value creation - Milestone revenue is lumpy and depends on partner progress - Supply chain and tariff changes can disrupt manufacturing economics - Competition in oncology is intense and globally well funded ## Accounting Revenue recognition is highly judgmental because MacroGenics earns income from milestones, options, research funding, manufacturing services, product sales, and royalties, each with different timing rules. Quarterly results can be volatile because milestone recognition depends on partner events, while the sale of future royalties creates a liability measured using Level 3 estimates and effective-interest accounting. Investors should also watch how the company accounts for manufacturing costs, royalty obligations, and any impairment or restructuring effects if programs are delayed. - **Collaboration and milestone revenue recognition** — Affects reported revenue mix and comparability across periods - **Contract manufacturing revenue and cost of services** — Impacts gross margin and operating leverage - **Liability related to sale of future royalties** — Can materially affect interest expense and balance sheet carrying value - **Royalty revenue timing** — Can create uneven quarterly revenue recognition - Milestone and collaboration revenue can shift sharply between quarters - Contract manufacturing revenue depends on production volume and service timing - Royalty-sale liability uses Level 3 estimates and effective interest accounting - Product sales ended after MARGENZA was sold to TerSera - Clinical-stage assets may require impairment or write-down review --- *Last updated: 2026-04-28T20:23:52.314513+00:00*